Non-alcoholic Steatohepatitis Registry Platform Study
Conditions: NASH With Fibrosis Sponsors: AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 9, 2023 Category: Research Source Type: clinical trials
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 Following Single and Multiple Ascending Doses Via Oral Administration to Healthy Participants
Conditions: Healthy Participants Interventions: Drug: AZD4144 Part A; Drug: AZD4144 Part B; Drug: Placebo Part A; Drug: Placebo Part B Sponsors: AstraZeneca; Parexel Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 8, 2023 Category: Research Source Type: clinical trials
First Line Treatment With Olaparib in Combination With Bevacizumab in HRD Positive Patients
Conditions: Carcinoma, Ovarian Epithelial Interventions: Drug: Olaparib; Drug: Bevacizumab Sponsors: Mario Negri Institute for Pharmacological Research; AstraZeneca Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 7, 2023 Category: Research Source Type: clinical trials
Upfront Maintenance Olaparib in Advanced Ovarian Cancer BRCAwt Patients With Known Homologous Recombination Deficiency
Conditions: Ovarian Cancer Interventions: Drug: Olaparib tablet Sponsors: Alexander B Olawaiye, MD; AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 7, 2023 Category: Research Source Type: clinical trials
AZD5305 vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents
Conditions: Metastatic Castration-Sensitive Prostate Cancer Interventions: Drug: AZD5305; Drug: Placebo; Drug: Abiraterone Acetate; Drug: Darolutamide; Drug: Enzalutamide Sponsors: AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 7, 2023 Category: Research Source Type: clinical trials
Chronic Kidney Disease Registry Platform Study
Conditions: Chronic Kidney Diseases Sponsors: AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 6, 2023 Category: Research Source Type: clinical trials
A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of Subcutaneous AZD6912 in Healthy Participants
Conditions: Rheumatoid Arthritis Interventions: Drug: AZD6912; Drug: Placebo Sponsors: AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 3, 2023 Category: Research Source Type: clinical trials
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
Conditions: Breast Cancer Interventions: Drug: Dato-DXd; Drug: Durvalumab; Drug: Pembrolizumab; Drug: Doxorubicin; Drug: Epirubicin; Drug: Cyclophosphamide; Drug: Paclitaxel; Drug: Carboplatin; Drug: Capecitabine; Drug: Olaparib Sponsors: AstraZeneca; Daiichi Sankyo, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 1, 2023 Category: Research Source Type: clinical trials
A Study of Rilvegostomig Plus Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection
Conditions: Biliary Tract Cancer Interventions: Drug: Rilvegostomig; Drug: Placebo; Drug: Capecitabine; Drug: Gemcitabine/Cisplatin; Drug: S-1 [Tegafur/Oteracil/gimeracil] Sponsors: AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 31, 2023 Category: Research Source Type: clinical trials
Impact of Long-acting Bronchodilator- -Corticoid Inhaled Therapy on Ventilation, Lung Function and Breathlessness
Conditions: Copd Interventions: Drug: TRIXEO AEROSPHERE Sponsors: University Hospital, Lille; AstraZeneca Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 31, 2023 Category: Research Source Type: clinical trials
A Phase I/II Study of AZD0305 for Relapsed/Refractory Multiple Myeloma
Conditions: Multiple Myeloma Interventions: Drug: AZD0305 Sponsors: AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 30, 2023 Category: Research Source Type: clinical trials
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
Conditions: Breast Cancer Interventions: Drug: Dato-DXd; Drug: Durvalumab; Drug: Paclitaxel; Drug: Nab-paclitaxel; Drug: Gemcitabine; Drug: Carboplatin; Drug: Pembrolizumab Sponsors: AstraZeneca; Daiichi Sankyo, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 27, 2023 Category: Research Source Type: clinical trials
A Placebo-controlled Safety and Tolerability Study of Intravenous (IV) and Subcutaneous (SC) AZD1163 in Healthy Volunteers
Conditions: Healthy Volunteers Interventions: Biological: AZD1163; Other: Placebo Sponsors: AstraZeneca; Parexel Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 27, 2023 Category: Research Source Type: clinical trials
PACCELIO - FDG-PET Based Small Volume Accelerated Immuno Chemoradiotherapy in Locally Advanced NSCLC
Conditions: Stage III Non-small Cell Lung Cancer; Locally Advanced; Unresectable Interventions: Radiation: standard Radiotherapy; Drug: Chemotherapy; Drug: Immunotherapy; Radiation: Experimental Radiotherapy Sponsors: TheraOp; AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 26, 2023 Category: Research Source Type: clinical trials
Harmonizing RCT-Duplicate Emulations In A Real World Replication Program (HARRP)
Conditions: Type 2 Diabetes Mellitus Interventions: Drug: Canagliflozin; Drug: DPP4 inhibitor; Drug: Liraglutide; Drug: Saxagliptin; Drug: 2nd generation Sulfonylurea Sponsors: AstraZeneca Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 25, 2023 Category: Research Source Type: clinical trials
